1338331-18-2

Upstream product

• 1163689-87-9 1,11-O-(di-tert-butylsilylene)-1,7,11-trideacetylpyripyropene 
• 1163689-88-0 7-O-p-cyanobenzoyl-1,11-O-(di-tert-butylsilylene)-1,7,11-trideacetylpyripyropene A 
• 1259032-84-2 (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-((di-tert-butylfluorosilyl)oxy)-12-hydroxy-4-(hydroxymethyl)-4,6a,12b-trimethyl-11-oxo-9-(pyridin-3-yl)-1,2,3,4,4a,5,6,6a,11,12,12a,12b-dodecahydrobenzo[f]pyrano[4,3-b]chromen-6-yl 4-cyanobenzoate 
• 20781-20-8 2,4-Dimethoxybenzylamine 
• 1338331-16-0 7-O-p-cyanobenzoyl-11-deacetoxymethyl-7-deacetyl-11-carboxy-pyripyropene A 
• 1259033-07-2 C₄₁H₄₇FN₂O₉Si 
• 1259033-08-3 C₄₁H₄₉FN₂O₉Si 

Relevant academic research and scientific papers

PYRIPYROPENE DERIVATIVE HAVING ACAT2 INHIBITING ACTIVITY AND STABLE TO METABOLIZING ENZYMES

A compound effective in prevention and treatment of arteriosclerosis with a mechanism different from that of statin drugs has the following formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein R1 is an aliphatic, alicyclic, or aromatic acyloxy group, or a group of the formula -O-CH(R7)-R8 where R7 is a lower alkoxy group and R8 is an aryl group, and R2 is carboxyl, a lower alkoxycarbonyl group, or an arylmethylcarbamoyl group, or a -CH2-acyloxy group and R3 is an aliphatic, alicyclic or aromatic acyloxy group, provided that at least one of R4 and R3 is a group other than acetoxy, or R2 and R3 taken together form a group of the formula -O-CH(R5)-O- where R5 is an aryl group.